Records

Papers

  1. Miyazaki T, Nakajima W, Hatano M, Shibata Y, Kuroki Y, Arisawa T, et al. Visualization of AMPA receptors in living human brain with positron emission tomography. Nat Med 2020;26:281–8. https://doi.org/10.1038/s41591-019-0723-9.

  2. Hatano M, Miyazaki T, Ishiwata Y, Nakajima W, Arisawa T, Kuroki Y, et al. Biodistribution and radiation dosimetry of the positron emission tomography probe for AMPA receptor, [11C]K-2, in healthy human subjects. Sci Rep 2021;11.
    https://doi.org/10.1038/s41598-021-81002-3.

  3. Arisawa T, Miyazaki T, Ota W, Sano A, Suyama K, Takada Y, et al. [11C]K-2 image with positron emission tomography represents cell surface AMPA receptors. Neurosci Res 2021;173:106–13. https://doi.org/10.1016/j.neures.2021.05.009.

 

Clinical Trial

Many clinical trials involving AMPA-PET have been performed, including physician-initiated clinical trials of automatic PET drug synthesizers. This is a list of tests that have been or are being conducted. The test details are linked to the test number (separate site).

Study Title Study No. Subject Number of cases Period
Clinical trial to evaluate the efficacy and safety of [11C]K-2 in healthy volunteers UMIN000020975 Healthy 8 2016/02/10 – end
The clinical trial to evaluate the efficacy of [11C]K-2 in refractory epilepsy patients undergoing anterior temporal lobectomy UMIN000025090 Refractory epilepsy 8 2016/11/30 –
The clinical pilot study to examine the distribution of [11C]K-2 in depression, bipolar disease, schizophrenia, addiction,ASD,epilepsy and FTD patients in oreder to develope the novel diagnostic method in cross-sectional way toward these diseases UMIN000025132 Mental ilness and healthy 110 2016/12/2 –
Clinical trial to examine the effective dose and the safety of [11C]K-2 synthesized by dedicated machine in healthy male volunteers UMIN000026357 Healthy 12 2017/3/6 – end
The exploratory clinical trial to evaluate the efficacy of [11C]K-2 in stroke patients under rehabilitation. UMIN000029952 Sequelae of cerebral infarction 20 2017/11/13 –
The clinical trial to examine the densities of AMPA receptors in epilepsy patients with [11C]K-2 UMIN000031624 Epilepsy 35 2018/4/1 –
Clinical trial to examine the effectiveness of AMPA-PET to identify epileptogenic focus in refractory epilepsy patients JapicCTI-194576 Refractory epilepsy 40 2019/1/16 –
Investigator-initiated clinical trial to evaluate the efficacy of AMPA-PET in functional recovery process by rehabilitation for subjects registered in the clinical phase II trial of T-817MA (T817MAJP201R trial) JapicCTI-194711 Stroke 10 2019/04/15 –
The relationship of AMPA receptor density with presence or absence of subsequent onset in high-risk cases of psychosis: A longitudinal PET study using [11C] K-2 jRCTs031190151 ARMS 30 2019/12/2 –
The relationship of AMPA receptor density in patients with autism spectrum disorder: A transversal PET study using [11C] K-2 jRCTs031190149 ASD 30 2019/12/2 –
The relationship of AMPA receptor density in patients with depression and bipolar disorder :a transversal PET study using [11C]K-2 jRCTs031190150 Depression, Bipolar disorder 60 2019/12/2 –
The relationship of AMPA receptor density in patients with schizophrenia: A transversal PET study using [11C] K-2 jRCTs031190197 Schizophrenia 30 2020/1/31 –
A pilot study to validate the estimate accuracy between standard uptake value ratio and non displaceable binding potential obtained from [11C]K-2 PET imaging in major cognitive disorders. jRCTs031190262 Dementia 92 2020/4/2 –
A transversal PET study using [11C]K-2 to investigate age-and-sex-related changes AMPA receptor density in healthy volunteers. jRCTs031200083 Healthy 100 2020/8/12 –